A Mayo Clinic study published in Communications Biology indicates that checkpoint immunotherapy reshapes the cellular microenvironment of tumor-draining lymph nodes in preclinical melanoma models. Led by Dr. Jessica Lancaster and Dr. Haidong Dong, researchers found that treatment reorganizes T cells, reduces metastatic tumor burden, and repositions macrophages into an immune-stimulating state away from T cells. The authors suggest renovating the full lymph node environment is crucial for effective cancer care.
Reorganization of the lymph node microenvironment
- ▪Senior author Jessica Lancaster noted that effective antitumor responses may require renovating the entire lymph node microenvironment rather than focusing solely on T cell activation.
- ▪Checkpoint immunotherapy reduced the amount of metastatic tumor inside lymph nodes and reorganized T cells, B cells, myeloid cells, and structural framework cells in a preclinical model.
- ▪A Mayo Clinic study published in Communications Biology found that checkpoint immunotherapy reorganizes the immune cell environment within lymph nodes affected by metastatic melanoma.
Effects on macrophages and myeloid cells
- ▪The Mayo Clinic study observed that macrophages shifted toward a more immune-stimulating state following checkpoint immunotherapy in melanoma-affected lymph nodes.
- ▪Mayo Clinic researcher Haidong Dong stated that myeloid cells, including macrophages, can be reprogrammed to help stimulate the immune response against cancer.
- ▪The Mayo Clinic study observed greater physical separation between macrophages and T cells following checkpoint immunotherapy, which may reduce suppressive immune interactions.
Study methodology and limitations
- ▪Mayo Clinic researchers combined advanced imaging with cellular and gene-expression analyses to evaluate tumor-draining lymph nodes in a preclinical melanoma metastasis model.
- ▪Mayo Clinic researchers cautioned that their findings were based on a preclinical model that does not fully replicate melanoma development and spread in human patients.
Study publication and funding
- ▪The study was authored by Ildefonso Silva-Junior, Haidong Dong, Jessica Lancaster, and colleagues, and published in Communications Biology in October 2026.
- ▪The Mayo Clinic research was supported by the National Institutes of Health, the Miltenyi Biotec Spatial Biology Award, and multiple cancer programs within the Mayo Clinic Comprehensive Cancer Center.
Background on immunotherapy and lymph nodes
- ▪Checkpoint immunotherapy helps the immune system attack cancer by blocking inhibitory signals that restrain T cell activation.
- ▪Lymph nodes serve as organized hubs where immune cells interact to initiate immune responses, making them key early sites for melanoma metastasis.
Story comments
Loading comments…